Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s shares declined 2.32% to $7.59. The company on Apr. 2 announced the appointment of Hugh M. Cole to the position of senior vice president and chief business officer. Mr. Cole will be responsible for global business and corporate development, licensing and strategic planning. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares after opening at $.79 moved to $ 7.80 on last trade day and at the end of the day closed at $7.58. Company price to sales ratio in past twelve months was calculated as 30.79 and price to cash ratio as 5.95. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) showed a negative weekly performance of -5.01%.
Merck & Co. (NYSE:MRK) Insider Bruce N. Kuhlik sold 145,225 shares of the stock in a transaction that occurred on Friday, April 4th. The stock was sold at an average price of $56.43, for a total value of $8,195,046.75. Following the completion of the sale, the insider now directly owns 121,845 shares in the company, valued at approximately $6,875,713. Merck & Co., Inc. (NYSE:MRK) shares fell -0.16% in last trading session and ended the day on $56.12. MRK return on equity ratio is recorded as 12.10% and its return on assets is 5.60%. Merck & Co., Inc. (NYSE:MRK) yearly performance is 31.77%.
Johnson & Johnson (NYSE:JNJ) image is undergoing a transformation as its pharmaceuticals business is becoming more significant. The company has traditionally been known for its medical devices and diagnostics equipment, but that is slowly changing. It recently announced the sale of its diagnostics unit, Ortho-Clinical Diagnostics, to Carlyle group for around $4 billion. [1] Ortho-Clinical Diagnostics manufactures and markets donor screening and blood typing products, besides being involved in information management, testing technologies, and automation and interpretation tools. Johnson & Johnson (NYSE:JNJ) shares moved up 0.16% in last trading session and was closed at $98.42, while trading in range of $98.32 – 99.38. Johnson & Johnson (NYSE:JNJ) year to date (YTD) performance is 8.23%.
Exelixis, Inc. (NASDAQ:EXEL)’s shares jumped 3.07% to $3.69. The company on Mar. 25 announced that the Independent Data Monitoring Committee (IDMC) notified the company that a planned interim analysis of the COMET-1 phase 3 pivotal trial has been completed, and that the IDMC recommended the trial proceed to its final analysis. Exelixis continues to anticipate top-line data from COMET-1 in 2014. Exelixis, Inc. (NASDAQ:EXEL) weekly performance is 7.10%. On last trading day company shares ended up $3.62. Exelixis, Inc. (NASDAQ:EXEL) distance from 50-day simple moving average (SMA50) is -43.77%. Analysts mean target price for the company is $7.38.
Leave a Reply